About Cover

The PSMA-targeting agent AuK aims to overcome renal hyperuptake in prostate cancer. Its radiotracer [^99mTc]Tc-AuK-NapLPRO-HYNIC-EDDA reduced kidney uptake while preserving tumor retention in mice, allowing for high-contrast SPECT/CT images within 2–4 hours and highlighting its clinical imaging potential.

View Online